INTRODUCTION AND OBJECTIVES: Accurate risk stratification after radical prostatectomy (RP) is important to help select men at risk of recurrence who will benefit most postoperative radiation or multimodal therapy. Increasingly genomic testing is being used in the clinic for this purpose. However, little is known about how these tests predict outcomes in African-American men (AAM), an underserved at risk population. Here we evaluate Decipher within a large Veteran Affairs cohort and compare its performance to the CAPRA-S clinical model for predicting outcomes in AAM and non-AAM RP patients.
METHODS: Decipher genomic classifier (GC) scores were generated for 557 PCa patients, who underwent RP at the Veteran Affairs Medical Center Durham between 1989 and 2016. This was a clinically high-risk cohort which all underwent RP and were selected to have either T3a, positive margins, seminal vesicle invasion, or received post-op radiation. Cox univariable and multivariable proportional hazards models and survival c-index were used to compare the performance of Decipher and CAPRA-S for predicting risk of metastasis and PCa specific mortality (PCSM).
RESULTS: Overall, 55% (n[306) of patients in the cohort were AAM. CAPRA-S classified 10.4% as low risk for recurrence while for GC it was 50.4%. With a median follow-up of 9 years, only 40 patients developed metastases and 18 patients died of PCa. CONCLUSIONS: Our results among non-AAM confirm many prior studies showing that GC is a powerful predictor of metastasis and PCSM. Among AAM, not only was GC a very strong predictor of poor outcome, there was actually a suggestion that GC may perform better among AAM than EAM, though this requires further validation.
